SVRA Savara Inc.

2.14
+0.02  (+1%)
Previous Close 2.12
Open 2.12
52 Week Low 0.69
52 Week High 5.48
Market Cap $115,835,044
Shares 54,128,525
Float 53,219,082
Enterprise Value $34,807,473
Volume 77,000
Av. Daily Volume 345,791
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
AeroVanc - AVAIL
MRSA in cystic fibrosis
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Molgradex - IMPALA
Autoimmune pulmonary alveolar proteinosis (PAP)
Phase 3
Phase 3
Phase 3 data June 12, 2019 did not meet primary endpoint. Second Phase 3 trial to commence 1Q 2021.
Molgradex - ENCORE
Nontuberculous mycobacterial (NTM) lung infection with cystic fibrosis (CF)
Phase 2a
Phase 2a
Phase 2a initiation announced April 1, 2019. Enrolment has been terminated due to COVID-19.
Molgradex - OPTIMA
Nontuberculous mycobacteria (NTM)
Phase 2a
Phase 2a
Phase 2 top-line data released March 12, 2020.
Aironite - INDIE
Heart failure with preserved ejection fraction (HFpEF)
Phase 2
Phase 2
Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint.

Latest News

  1. Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Study Expected to Start in Q1 2021

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

    "With a final design for IMPALA 2, we are working diligently on study preparations and expect it to start in the first quarter of next year," said Rob Neville, Chief Executive Officer, Savara. "Building on the learnings from the first IMPALA study, and following constructive discussions with the regulatory agencies, we are confident in the study design and believe IMPALA 2 will effectively measure…

    Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Study Expected to Start in Q1 2021

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

    "With a final design for IMPALA 2, we are working diligently on study preparations and expect it to start in the first quarter of next year," said Rob Neville, Chief Executive Officer, Savara. "Building on the learnings from the first IMPALA study, and following constructive discussions with the regulatory agencies, we are confident in the study design and believe IMPALA 2 will effectively measure the potential efficacy and safety of Molgradex to treat aPAP."

    Recent Developments

    Molgradex for aPAP

    • The Phase 3 IMPALA 2 study, which incorporates feedback from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), will be a randomized, double-blind, placebo-controlled study evaluating Molgradex for the treatment of aPAP. A total of 160 patients will be enrolled at approximately 50 sites across the U.S., Canada, Japan, South Korea, and select countries in Europe. Patients will be randomized in one of two arms: Molgradex 300 µg administered once-daily continuously or matching placebo. The primary endpoint will be change from baseline to week 24 in diffusion capacity of the lungs (DLCO) percent predicted. Secondary endpoints will be change in baseline to week 24 in St. George's Respiratory Questionnaire (SGRQ) Total Score, SGRQ Activity Component, and exercise capacity using a treadmill test. While efficacy endpoints will be assessed at week 24 for primary analyses, the placebo-controlled period will be 48 weeks to better assess the durability of treatment effect, as well as long-term safety of the drug, which is intended to be administered chronically. At the end of the 48-week double-blind period, both treatment arms will rollover into a 48-week open-label follow-on period in which all patients will receive Molgradex 300 µg administered once-daily.
    • The study is expected to start in the first quarter of 2021.

    Apulmiq for non-cystic fibrosis bronchiectasis (NCFB)

    • The Company is further analyzing data from the previous Apulmiq development program and is also working on the design of a future program, with inputs from external bronchiectasis experts, for future discussion with the FDA.

    AeroVanc for methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF)

    • In March 2020, the Phase 3 AVAIL study stopped enrolling new patients due to COVID-19 concerns. Total target enrollment was 200 patients. Enrollment in the adult population completed, with 55 patients out of a target of 50. One hundred and thirty-three patients were enrolled in the primary analysis population (younger patients between 6-21 years of age) out of a target of 150.
    • Top line results from AVAIL are still expected in early 2021.

    Molgradex for nontuberculous mycobacterial (NTM) lung infection

    • In March 2020, the exploratory ENCORE study stopped enrolling new patients due to COVID-19 concerns. Fourteen patients out of a target of ~30 were enrolled. Despite closing enrollment early, data from the enrolled patients will provide useful information on Molgradex in people living with CF who have NTM lung infection.

    Second Quarter Financial Results (Unaudited)

    The Company's net loss attributable to common stockholders for the three months ended June 30, 2020 was $9.4 million, or $(0.16) per share, compared with a net loss attributable to common stockholders of $21.9 million, or $(0.57) per share, for the three months ended June 30, 2019.

    Research and development expenses decreased by $4.4 million, or 41.9%, to $6.1 million for the three months ended June 30, 2020 from $10.5 million for the three months ended June 30, 2019. The decrease was primarily related to ~$2.8 million in lower AVAIL clinical study costs due to the close of enrollment in the study, the transition to processing the last patient out and database management and lock, and a reduction in CMC and clinical operations activities. Additionally, there was a decrease of ~$1.6 million in costs associated with the Molgradex aPAP program as study activities associated with IMPALA have concluded and preparations for a second Molgradex Phase 3 study (IMPALA 2) are underway.

    General and administrative expenses decreased by $1.1 million, or 26.0%, to $3.1 million for the three months ended June 30, 2020 from $4.2 million for the three months ended June 30, 2019. The decrease was primarily due to reduced commercial activities for the three months ended June 30, 2020.

    As of June 30, 2020, the Company had a carrying value of its debt of ~$24.9 million and had cash, cash equivalents, and short-term investments of ~$100 million. The Company anticipates an additional ~$46.0 million in gross proceeds from the second tranche of the December 2019 financing.

    Conference Call/Webcast

    Savara management will host a conference call/webcast today at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT). Shareholders and other interested parties may access the call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the "Savara Inc." call. A live webcast of the call can be accessed on the Investors page of Savara's website at https://www.savarapharma.com/investors/events-presentations/.

    Approximately one hour after the call, a telephone replay will be available and will remain available through August 13, 2020 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 from elsewhere outside the U.S. and entering the replay access code 10146176. A webcast replay will be available on the Investors page of Savara's website and will remain available for 30 days.

    About Savara

    Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara's strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

    Forward Looking Statements

    Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements regarding the expected timing of the start of the IMPALA 2 study; the planned study design for IMPALA 2; that we are confident in the IMPALA 2 study design and believe the study will effectively measure the potential efficacy and safety of Molgradex to treat aPAP; our plans for the design of the Apulmiq development program, including discussions with the FDA; that top line results from AVAIL are expected in early 2021; our expectations for the data from the ENCORE study; and that we anticipate an additional ~$46.0 million in gross proceeds from the second tranche of the December 2019 financing. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks and uncertainties relating to the impact of the COVID-19 pandemic on our business and operations, the outcome of our future interactions with regulatory authorities, the outcome of our ongoing and planned clinical trials for our product candidates, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs, the closing of the second tranche of funding from the December 2019 financing, the ability to obtain the necessary patient enrollment for our product candidates in a timely manner, the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex, Apulmiq, and AeroVanc that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

    Savara Inc. and Subsidiaries
    Condensed Consolidated Statements of Operations
    (in thousands, except for share and per share amounts)
    (Unaudited)
     
    Three months ended Six months ended
    June 30, June 30,

    2020

    2019

    2020

    2019

    Operating expenses:
    Research and development

    $

    6,079

     

    $

    10,464

     

    $

    19,279

     

    $

    20,483

     

    General and administration

     

    3,117

     

     

    4,211

     

     

    6,099

     

     

    6,974

     

    Impairment of goodwill

     

    -

     

     

    7,420

     

     

    -

     

     

    7,420

     

    Depreciation and amortization

     

    68

     

     

    59

     

     

    126

     

     

    197

     

    Total operating expenses

     

    9,264

     

     

    22,154

     

     

    25,504

     

     

    35,074

     

     
    Loss from operations

    $

    (9,264

    )

    $

    (22,154

    )

    $

    (25,504

    )

    $

    (35,074

    )

     
    Other income (expense), net

     

    (125

    )

     

    215

     

     

    693

     

     

    1,023

     

     
    Net loss attributable to common stockholders

    $

    (9,389

    )

    $

    (21,939

    )

    $

    (24,811

    )

    $

    (34,051

    )

     
    Net loss per share - basic and diluted

    $

    (0.16

    )

    $

    (0.57

    )

    $

    (0.43

    )

    $

    (0.91

    )

     
    Weighted average shares - basic and diluted

     

    58,858,216

     

     

    38,440,647

     

     

    58,111,225

     

     

    37,235,209

     

     
    Other comprehensive income

     

    247

     

     

    211

     

     

    136

     

     

    12

     

     
    Total comprehensive loss

    $

    (9,142

    )

    $

    (21,728

    )

    $

    (24,675

    )

    $

    (34,039

    )

     
     
    Savara Inc. and Subsidiaries
    Condensed Consolidated Balance Sheet data
    (in thousands)
    (Unaudited)
     
    June 30, December 31,

    2020

    2019

    Cash, cash equivalents, and short-term investments

    $

    99,609

    $

    121,761

     
    Working capital

     

    96,109

     

    113,187

     
    Total assets

     

    115,146

     

    136,203

     
    Total liabilities

     

    31,348

     

    34,505

     
    Stockholders' equity

     

    83,798

     

    101,698

     

    View Full Article Hide Full Article
  2. Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

    Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 30 days.

    About Savara

    Savara is an orphan lung disease…

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

    Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 30 days.

    About Savara

    Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara's strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

    View Full Article Hide Full Article
  3. Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).

    Shareholders and other interested parties may access the call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the "Savara Inc." call. A live webcast of the call can be accessed on the Investors page of Savara's website at https://www.savarapharma.com/investors/events-presentations/.

    Approximately one hour after the call, a telephone replay will…

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).

    Shareholders and other interested parties may access the call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the "Savara Inc." call. A live webcast of the call can be accessed on the Investors page of Savara's website at https://www.savarapharma.com/investors/events-presentations/.

    Approximately one hour after the call, a telephone replay will be available and will remain available through August 13, 2020 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 from elsewhere outside the U.S. and entering the replay access code 10146176. A webcast replay will be available on the Investors page of Savara's website and will remain available for 30 days.

    About Savara

    Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara's strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

    View Full Article Hide Full Article
  4. Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.

    Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 90 days.

    About Savara

    Savara is an orphan lung disease company with a pipeline comprised of three investigational…

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.

    Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 90 days.

    About Savara

    Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled liposomal ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara's strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

    View Full Article Hide Full Article
  5. Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the COVID-19 pandemic and in the interest of the health and well-being of stockholders and other meeting participants. The Annual Meeting will now be held in a virtual-only format by means of a live audio webcast at 3:00 p.m. CDT on Friday, May 29, 2020, instead of the location, time, and date previously disclosed in the proxy materials filed with the Securities and Exchange Commission on April 15, 2020. Stockholders will not be able to attend the Annual Meeting in person…

    Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the COVID-19 pandemic and in the interest of the health and well-being of stockholders and other meeting participants. The Annual Meeting will now be held in a virtual-only format by means of a live audio webcast at 3:00 p.m. CDT on Friday, May 29, 2020, instead of the location, time, and date previously disclosed in the proxy materials filed with the Securities and Exchange Commission on April 15, 2020. Stockholders will not be able to attend the Annual Meeting in person.

    As described in the proxy materials, all stockholders of record at the close of business on March 30, 2020, and those who hold a legal proxy, are entitled to participate in and vote at the Annual Meeting. Stockholders can attend the Annual Meeting by accessing www.virtualshareholdermeeting.com/SVRA2020 and entering the 16-digit control number on the proxy card or notice of availability of proxy materials previously furnished. Guests may attend the Annual Meeting without a control number but will not be able to vote or ask questions.

    All stockholders are encouraged to submit their vote by proxy in advance by one of the methods described in the proxy materials, even if they plan to attend the Annual Meeting. The proxy card previously furnished will not be updated to reflect the change in date, time, and location and may continue to be used to vote in connection with the Annual Meeting.

    About Savara

    Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis and cystic fibrosis-affected individuals. Apulmiq is an inhaled liposomal ciprofloxacin in Phase 3 development for non-cystic fibrosis bronchiectasis (NCFB). AeroVanc is an inhaled vancomycin in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people living with cystic fibrosis. Savara's strategy involves broadening its pipeline through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

    View Full Article Hide Full Article
View All Savara Inc. News